Innovating Beyond
Next-generation therapies for serious respiratory diseases
We are dedicated to advancing transformative medicines for people living with serious respiratory diseases, leveraging bold science shaped by patients’ lived experiences. Our lead program, deupirfenidone, is entering Phase 3 development for idiopathic pulmonary fibrosis (IPF) and has the potential to redefine the standard of care for fibrotic lung diseases.
Advancing the first superiority trial in IPF
SURPASS-IPF, the first industry-sponsored head-to-head Phase 3 trial in IPF, is designed to evaluate the superiority of deupirfenidone against an approved antifibrotic therapy.
Deupirfenidone: A potential new standard of care for IPF
Investigational medication:
Oral tablet
Clinical progress:
Phase 2b completed;
Phase 3-ready
Regulatory:
Orphan Drug Designation granted by the U.S. FDA and European Commission
Deupirfenidone is a next-generation antifibrotic being developed as a potential new standard of care for IPF.
Builds on established efficacy and safety of FDA-approved pirfenidone
Deupirfenidone is a strategically modified version of an approved IPF treatment
Potential for reduced lung function decline
In a Phase 2b trial, deupirfenidone slowed lung function decline to the range expected with healthy aging over 26 weeks
Durable treatment response
In a Phase 2b trial and open-label extension, the treatment effect demonstrated with deupirfenidone was maintained out to at least 52 weeks
A new path forward for IPF
We believe advancing care in IPF requires more than scientific innovation alone. From clinical trial design to patient engagement, we are integrating the lived experiences of people with IPF into the development of deupirfenidone.
